Special Report: KRAS Finding Changes Oncology Practice But Poses Profound Regulatory Dilemma
FDA Concerned About Data-Dredging In Drug-Diagnostic Applications
Government Offers Two Approval Standards For Assays: CLIA, FDA
FDA Ponders Standards For “Retrospective Prospective” Studies
ODAC Discussion: NCI’s Richard Simon Cautions About Rules Of Thumb
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- Trump targets HHS in $810M appropriations clawback
- Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?









